Mazor Robotics posts first earnings since Medtronic deal

surgical robots

Medtronic’s ($MDT) robotic surgery partner Mazor Robotics ($MZOR) reported earnings Tuesday, the first time it has done so since tying up with the device giant earlier this year.

In May, the duo made two agreements involving co-promotion, co-development and commercial distribution worth up to $50 million to come in three potential tranches. In mid-July, Mazor met its first milestone--the launch of its Mazor X guidance platform for spinal surgeries--and stood to collect up to $20 million in a second tranche. This was on top of the $11.9 million it picked up when it inked the deals.

For the quarter ended June 30, Mazor posted $8.3 million in revenues, up 30% from $6.4 million the previous quarter and up 6% from $7.8 million one year prior. Meanwhile, the net loss for the quarter stood at $4.1 million, compared to $5.1 million the previous quarter and $2.1 million a year prior. And the company used $600,000 in cash for operating activities, while cash, cash equivalents and investments tallied up to $47.5 million, including the $11.9 million from Medtronic.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

CEO Ori Hadomi expects to take the first year of its deal with Medtronic to “synchronize” the duo, anticipating “significant growth” in the second year and second stage of the agreements. Mazor has bolstered its sales team considerably, with the addition of hundreds of Medtronic reps. The combined sales force will focus on increasing awareness and interest in the Mazor X platform among surgeons in the U.S.

On the earnings call, Hadomi reiterated that the partnership with Medtronic is focused only on using Mazor X for spinal surgeries, but said that it may be expanded in the future to include collaboration on brain procedures.

In July, Mazor unveiled two new studies for its Renaissance robotic spinal surgery system. The first study showed that freehand minimally invasive surgery and freehand open surgery had three times the rate of complications than procedures conducted using Renaissance. Freehand surgeries also had 3.8 times the rate of surgery revision than surgeries using Renaissance. The second study indicated that using Renaissance significantly reduced the complication and revision rates when compared to traditional freehand surgery.

- here's the earnings transcript

Related Articles:
Medtronic’s robotic surgery partner Mazor unveils studies touting effectiveness of its machines
Mazor picks up $20M from Medtronic as it launches spine surgery robot
Medtronic details artificial pancreas plans, as well as Mazor, Qualcomm deals
Medtronic enters robotic spinal surgery in a partnership with, investment in Israeli small cap

Read more on

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.